Sarepta Therapeutics Inc (NASDAQ:SRPT), a developer of innovative RNA-targeted therapeutics, today reported financial results for the three and six months ended June 30, 2016, …
Cowen analyst Ritu Baral‘s stance on eteplirsen, Sarepta Therapeutics Inc (NASDAQ:SRPT) pipeline drug for Duchenne Muscular Dystrophy, DMD, is unchanged. This comes after Santhera …
RBC Capital analyst Simos Simeonidis weighed in today on Sarepta Therapeutics Inc (NASDAQ:SRPT), after the FDA refused to allow competitor Santhera accelerated approval for its Duchenne muscular …
In a research report issued Friday, William Blair analyst Tim Lugo reiterated a Market Perform rating on shares of Sarepta Therapeutics Inc (NASDAQ:SRPT), after …
Oppenheimer analyst Christopher Marai was out pounding the table on Sarepta Therapeutics Inc (NASDAQ:SRPT) Monday, reiterating an Outperform rating and price target of $60, which …
Gilead Sciences, Inc. Leerink Swann analyst Geoff Porges reiterated an Outperform rating on shares of Gilead Sciences, Inc.
Sarepta Therapeutics Inc (NASDAQ:SRPT), a developer of innovative RNA-targeted therapeutics, today announced that Sarepta, throughCredit Suisse and Robert W. Baird & Co.
Sarepta Therapeutics Inc Shares of Sarepta Therapeutics Inc (NASDAQ:SRPT) are on the rise today, after the biotech firm received a request from the FDA to provide additional data …
Valeant Pharmaceuticals Intl Inc (NYSE:VRX) and Sarepta Therapeutics Inc (NASDAQ:SRPT) are two of this morning’s biggest gainers and losers. One top analyst continues …
Sarepta Therapeutics Inc (NASDAQ:SRPT), a developer of innovative RNA-targeted therapeutics, today announced that the U.S.
